Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Idiopathic achalasia
Idiopathic achalasia
Idiopathic achalasia
Synonyms: Achalasia cardia, Idiopathic achalasia of esophagus, Primary achalasia
Synonyms: Achalasia cardia, Idiopathic achalasia of esophagus, Primary achalasia
Synonyms: Achalasia cardia, Idiopathic achalasia of esophagus, Primary achalasia
Drug discovery
2,416
papers
On emerging therapies
Rare gastroenterologic diseases
Idiopathic achalasia
Overview
Idiopathic achalasia is a rare esophageal motility disorder characterized by aperistalsis of the esophageal body and impaired lower esophageal sphincter (LES) relaxation, leading to dysphagia, regurgitation, chest pain, and weight loss. Etiology involves autoimmune, neurogenic, or viral-mediated degeneration of inhibitory neurons. Diagnosis relies on high-resolution manometry (subtypes I-III), barium swallow, and endoscopy to exclude malignancy [1][2][6].
Therapies
First-line: Graded pneumatic dilation or laparoscopic Heller myotomy with partial fundoplication [1][5][8].
Peroral endoscopic myotomy (POEM) preferred for type III achalasia and offers durability comparable to surgery [8][12].
Botulinum toxin injections reserved for frail patients due to short-term efficacy [9][12].
Categories: rare gastroenterological diseases
Research Papers
2,416 drug discovery papers about Idiopathic achalasia. Recent publications:
2,416 drug discovery papers about Idiopathic achalasia. Recent publications:
categories:
Small molecules
small molecules
2026-08-28 | Intraoperative indocyanine green (ICG) fluorescence to assess mucosal integrity during laparoscopic Heller-Dor surgery: a pilot randomized study.
Achalasia is a rare oesophageal motility disorder, and minimally invasive Heller-Dor (HD) surgery remains the gold standard surgical treatment for type I and II disease. Mucosal injury is a relevant intraoperative risk during laparoscopic Heller-Dor (LHD) myotomy. Real-time assessment of mucosal integrity remains challenging. This study aimed to evaluate whether the intraoperative use of Indocyanine Green (ICG) fluorescence during this surgery could reliably assess mucosal integrity and potentially reduce the need for intra- and postoperative additional diagnostic tests. In this prospective pilot randomized study, patients undergoing LHD for type I-II achalasia were randomly assigned (1:1) to intraoperative ICG fluorescence assessment or standard intraoperative evaluation with endoscopy and postoperative contrast radiography. The primary outcome was intraoperative detection of mucosal leaks. Secondary outcomes included operative time, intraoperative and postoperative complications, length of stay, postoperative pain, inflammatory markers, dietary progression and 12-month follow-up (ClinicalTrials.gov Identifier: NCT07181070). Seventy-one patients were included (37 ICG, 34 standard). No significant differences were observed between groups in intraoperative or postoperative complications, postoperative recovery, or inflammatory markers. Operative time was significantly shorter in the ICG group compared with the standard group (median 95 [90-95] vs. 105 [95-110] minutes; p = 0.04). Intraoperative ICG fluorescence is safe and feasible, providing real-time visualization of mucosal integrity during LHD surgery. This technique may represent a valuable adjunct to standard practice, optimizing surgical efficiency and resource utilization. Larger studies are needed to confirm these findings.
2026-06-09 | Prucalopride for recurrent achalasia in a pediatric patient: a Case Report
: Introduction Prucalopride, a prokinetic agent, is beneficial for chronic idiopathic constipation in pediatrics, but its efficacy for upper gastrointestinal motility disorders has not been well explored. Case presentation We present an 11-year old male with type II achalasia who underwent Heller myotomy and Dor fundoplication at age 9 and had recurrence of symptoms one year post-operatively. The patient was evaluated with esophagogastroduodenoscopy (EGD) with biopsy and Functional Luminal Impedance Planimetry Probe (FLIP). Symptoms were determined to be secondary to esophageal dysmotility with ongoing esophagogastrojunction (EGJ) outlet obstruction. The patient had resolution of dysphagia and age-appropriate weight gain after starting prucalopride at 1mg dose, daily, by mouth. His symptoms improved within 30 days after initiation. As of last known follow-up 12 months later, he remained symptom free. We expect to continue the current management indefinitely so long as symptoms remain controlled. Conclusion Prucalopride may be a safe and beneficial escalation of therapy in an attempt to delay or avoid further surgical intervention.
2026-03-25 | Severe pneumonia and bloodstream dissemination caused by Mycobacterium houstonense in a patient with achalasia: clinical importance of genospecies typing.
BACKGROUND: Infections caused by members of the Mycobacterium fortuitum complex are generally mild and confined to skin and soft tissues, while severe disease in immunocompetent individuals is uncommon. Within the Mycobacterium fortuitum complex, the unnamed third biovariant complex comprises several closely related species that cannot be reliably distinguished using routine molecular diagnostic methods. Importantly, species within this complex show marked interspecies variability in antimicrobial susceptibility, including predictable intrinsic resistance patterns, with direct consequences for empiric treatment selection in severe infections. Because antimicrobial susceptibility testing for rapidly growing mycobacteria typically requires at least one week, rapid and accurate species-level identification is essential to guide effective early therapy. CASE PRESENTATION: We report a case of life-threatening pneumonia with bloodstream dissemination caused by a third-biovariant M. fortuitum complex species in an otherwise immunocompetent 44-year-old woman with previously undiagnosed achalasia. Routine diagnostics identified the isolate as belonging to the M. fortuitum complex but were insufficient for species-level identification. Whole-genome sequencing was performed and identified the pathogen as Mycobacterium houstonense, a species historically considered rare in human disease. The patient developed severe respiratory failure and sepsis, requiring prolonged intensive care treatment. Targeted antimicrobial therapy guided by species identification, combined with treatment of the underlying achalasia, led to gradual clinical improvement, although prolonged antimicrobial therapy was required to achieve culture conversion. CONCLUSIONS: This case represents, to our knowledge, the first reported case in which M. houstonense was isolated from blood cultures in association with invasive disease. It demonstrates that infections caused by species within the unnamed third biovariant M. fortuitum complex can be severe and that reliance on complex-level identification alone may delay appropriate empiric therapy. Rapid genospecies identification is therefore crucial in severe infections caused by species within the unnamed third biovariant M. fortuitum complex, particularly when antimicrobial susceptibility is known to vary markedly between closely related species.
2026-01-01 | Experience in administration of an esophageal protective agent in patients with achalasia cardia and Barrett's esophagus
Achalasia cardia (AC) and Barrett's esophagus (BE) are precancerous conditions whose relevance is associated with a significant increase in the morbidity over the past 30 years and a high risk of esophageal adenocarcinoma. Despite different mechanisms of development, these diseases have similar clinical presentations (regurgitation, swallowing disorders, cough, chest pain, heartburn) and share some tissue changes related to inflammation in the esophageal mucosa. Gastroesophageal reflux disease (GERD) plays a key role in both conditions: as a cause of BE and as an adverse clinical outcome in patients wi th AC. Both diseases share a common mechanism of tissue changes suc h as damaged mucosal barrier, impaired apical junction complex, dilated intercellular spaces, and the disease progression. In patients with AC, pneumatic dilation of the cardia and incision of the esophagogastric junction muscles lead to damage of muscle fibers and inflammation. As for BE, radiofrequency ablation of the metaplastic esophageal tissue also affects the mucosa. Clinical case reports of patients with BE and AC demonstrate efficacy of an esophageal protective agent including sodium hyaluronate, sodium chondroitin sulfate, and Poloxamer 407. Owing to reliable protection of the esophageal mucosa, inflammation reduction, and recovery of intercellular connections, it may be used to treat BE and AC along with background therapy. KEYWORDS: Barrett's esophagus, achalasia cardia, GERD, esophageal protective agent, case reports. FOR CITATION: Ufimtseva I.V., Yakovleva S.V., Blagikh A.V. Experience in administration of an esophageal protective agent in patients with achalasia cardia and Barrett's esophagus. Russian Medical Inquiry. 2026;10(5):326–333 (in Russ.). DOI: 10.32364/2587-6821- 2026-10-5-9
2025-11-17 | Postoperative Nausea and Vomiting Between Total Intravenous and Sevoflurane Anesthesia after Peroral Endoscopic Myotomy; A Randomized, Double-Blind
Peroral endoscopic myotomy (POEM) recently has been reported as minimally invasive therapy for esophageal achalasia requires general anesthesia. Postoperative nausea and vomiting (PONV) is one of the most common adverse events after general anesthesia. Although PONV is associated with adverse consequences undergoing POEM, little has been known about the incidence and risk factors. We evaluated the incidence of PONV undergoing POEM as well as the relationship between incidences and anesthetic agents. This prospective double-blind study comprised 60 patients with American Society of Anesthesiologist physical status I or II who were undergoing POEM with inhaled anesthesia or TIVA. Patients were interviewed by two experienced anesthesiologists about incidence of PONV in accordance with a categorical verbal rating scale (VAS) and PONV Intensity Scale. The primary outcome was the incidence of PONV undergoing POEM between the two groups. In addition, we observed postoperative outcomes including bleeding at surgical site, mucosal injury, and patients’ satisfaction. The incidence of PONV after POEM within first 6 hours was significant lower in the TIVA group than in the sevoflurane group (46.4% vs 76.7%, p=0.025). Additionally, it was observed that number of patients who experienced postoperative complications, such as surgical site injury, mucosal injury, heart burn, pneumoperitoneum, and emphysema, was higher in TIVA group (44.4%) compared with in sevoflurane group (26.7%), but it was insignificant (p=0.130). These data suggest that TIVA could be considered as a good method to prevent PONV during early postoperative period (within 6 hours) after POEM.
proteins
2025-11-14 | Clinical Utility of Botulinum Toxin Injections in Children with Gastrointestinal Disorders.
To review the clinical utility of botulinum toxin (BTX) injections in children with gastrointestinal (GI) disorders. BTX is a presynaptic acetylcholine inhibitor with medical indications ranging from the treatment of muscle spasticity to gastrointestinal disorders involving sphincter dysfunction. BTX injections to the upper esophageal sphincter are used to target cricopharyngeal achalasia and retrograde cricopharyngeal dysfunction as temporary measures to decrease sphincter tone and improve swallowing, potentially eliminating the need for surgery. Lower esophageal and pyloric BTX injections have shown benefit in achalasia and gastroparesis, particularly in children unable to undergo or refractory to definitive treatments. Anorectal indications represent the largest experience, especially in children with persistent obstructive defecation symptoms after surgery for Hirschsprung's disease. BTX injection is a minimally invasive, reversible, and generally well-tolerated intervention with mild, self-limited side effects. However, its limitations include transient effects, procedural variability, and primarily off-label use, with most pediatric experience derived from small series. Prospective studies are needed to further evaluate patient selection, standardization, dosage, and long-term efficacy in pediatric gastrointestinal disorders.
2025-09-29 | Diagnostic and Therapeutic Challenges in a Case of Achalasia Masquerading as Gastroesophageal Reflux Disease (GERD).
Achalasia is a rare swallowing disorder that occurs due to the deterioration of the inhibitory neurons that control the lower esophageal sphincter (LES). Achalasia shares many clinical characteristics and symptoms with gastroesophageal reflux disease (GERD), a common process involving reflux of stomach acid into the esophagus, causing difficulties in differentiating diagnoses for therapeutic management. We report the case of a 49-year-old male patient with a history of chronic GERD who presented with dysphagia. Despite proton pump inhibitor (PPI) therapy, the patient developed worsening dysphagia. Esophagogastroduodenoscopy (EGD) suggested a diagnosis of achalasia, later confirmed with barium esophagram and manometry. Due to worsening symptoms and concerns about surgical fitness, the patient underwent bridge Botox therapy. However, further deterioration necessitated surgical myotomy. This case highlights the importance of a full dysphagia evaluation, including barium esophagram and EGD. This case also highlights the treatment of achalasia, which may include Botox injections as bridge therapy and myotomy for complete resolution.
2025-09-22 | When Two Roads Intersect: Coexisting Achalasia Cardia and Oesophageal Varices as a Therapeutic Dilemma.
Achalasia is a rare cause of oesophageal dysmotility. This disorder causes impaired relaxation of the lower oesophageal sphincter (LOS), impacting peristalsis and the normal movement of food through the digestive tract, resulting in worsening swallowing difficulty, known as dysphagia. Although various effective treatments are available, like pneumatic dilation, laparoscopic Heller myotomy, and peroral endoscopic myotomy (POEM), patients with portal hypertension may develop oesophageal varices, which complicates treatment due to the heightened risk of severe bleeding. We present the case of a 45-year-old man with a history of cirrhosis and chronic hepatitis C who developed progressively worsening dysphagia over four months, which led to significant weight loss over this period and prompted further investigation. An oesophagogastroduodenoscopy (OGD) showed a dilated oesophagus with retained food contents and grade II oesophageal varices without any endoscopic red signs. Additionally, a barium swallow and high-resolution manometry were done, which led to the confirmation of the diagnosis of achalasia cardia. Given the high risk of bleeding associated with conventional therapies in the presence of varices, a safer, minimally invasive approach was chosen. Botulinum toxin was carefully injected into the LOS under endoscopic ultrasound (EUS) guidance to avoid the variceal sites and negate the risk of bleeding. This approach allowed targeted treatment of achalasia while minimising the risk of variceal bleeding. The patient experienced significant improvement in dysphagia without complications. This case highlights the rare and challenging coexistence of achalasia and oesophageal varices. It highlights the need for considering individualised treatment strategies in high-risk individuals.
2025-08-27 | Efficacy of esophageal balloon dilatation with Botox injection in children with achalasia referred to a tertiary care center.
Achalasia is an esophageal motility disorder with symptoms like regurgitation, dysphagia, anorexia, and chronic cough. Effective treatments include pneumatic dilatation and myotomy. This study evaluated the combined use of botulinum toxin (Botox) injection and esophageal balloon dilation versus balloon dilation alone, analyzing recovery rates for gastrointestinal and non-gastrointestinal symptoms. This clinical trial involved an intervention group and historical controls. Patients with symptomatic achalasia referred to Mofid Hospital (2020-2023) received balloon dilatation with Botox injection. Historical controls had balloon dilatation alone. Botox was injected in the Lower Esophageal Sphincter (LES) at four points before balloon dilatation. Symptoms and growth parameters were monitored every three months for a year, then every six months, with annual follow-ups for three years. The study included 37 intervention and 31 control patients, and data were analyzed using SPSS 24 software. From the onset of the study to the 36th month, the intervention group showed greater symptom improvement than the control group: nausea or vomiting (21.8%), regurgitation (37.2%), dysphagia to liquids (25%), dysphagia to solids (25.6%), Globus sensation (13.5%), anorexia (19.6%), weight loss (21.3%), halitosis (22.3%), cough (16.8%), aspiration (20%), and refusal to eat (7%). Exceptions were chest pain (almost the same in both groups) and heartburn (1.1% better in the control group). At 6 and 12 months, the intervention group improved in abdominal tenderness (9.8%), wheezing (11.9%), and coarse rales (16.8%). Radiological signs improved more in the intervention group: esophageal dilatation (9.8%), rat tail/bird beak sign (33.7%), tertiary contractions (6.5%), and reduced air-fluid level 3 and 2 in the esophagus respectively (upper to middle third: 12.5%, middle to lower third: 8.4%) and the exception was sigmoid esophagus which was almost the same in both groups (3.9%). At 36 months, growth criteria in the intervention group increased: length (5.8 cm), BMI (1.87 units), Z score (0.91 units), and percentile (14.7 units). The combined balloon and Botox treatment has shown effectiveness in improving disease symptoms, physical examination results, growth criteria, and radiological findings. Further studies are recommended to establish this approach as a potential national protocol.
2024-10-07 | Botulinum toxin injection of the lower esophageal sphincter to identify achalasia-variant esophagogastric junction outflow obstruction.
Esophagogastric junction outflow obstruction (EGJOO) can be an achalasia variant caused by neuromuscular dysfunction of the lower esophageal sphincter (LES), or the manometric manifestation of mechanical processes that impair EGJ distensibility. Distinction among these conditions has important implications for treatment, but can be difficult. We hypothesized that response to botulinum toxin (BT) injection of the LES could be a diagnostic test for identifying achalasia-variant EGJOO likely to respond to LES muscle-directed invasive therapy. We reviewed our experience with symptomatic EGJOO patients who had BT injection of the LES. Data collected include demographics, esophageal body manometry findings, esophagram evidence of retention, and symptom response at 1-6 months after BT injection categorized as poor, partial, or good. Clinical response to any subsequent LES-directed invasive treatment (EsoFLIP dilation, pneumatic dilation, Heller myotomy, or POEM) also was recorded. Thirteen symptomatic EGJOO patients were included (mean age 55.9 ± 16.4 years; eight men, five women). Symptom response to BT injection was good in six (46%), partial in three (23%), and poor in three (23%); one was lost to follow-up. All five patients who received invasive treatment after partial or good response to BT had a partial or good response to invasive treatment. The one patient who had invasive treatment after a poor response to BT had a poor response to invasive treatment. These findings suggest that a good response to BT injection of the LES can identify an achalasia-variant form of EGJOO that will respond to LES muscle-directed invasive therapy.
antibodies
2026-05-26 | A frameshift variant in FAM129C contributes to achalasia through B cell responses against the GABAA receptor.
Achalasia is a rare esophageal motility disorder of poorly understood etiology. Here, we perform a large trio-based whole-genome sequencing study of achalasia and identify a recessively inherited frameshift variant in FAM129C (p.Ala454fs). A CRISPR/Cas9-engineered Fam129c-mutant mouse model recapitulating key features of achalasia was established, including growth retardation, elevated lower esophageal sphincter (LES) pressure, and selective loss of inhibitory neurons. Multi-omic analyses revealed substantial B cell expansion and activation within the LES, accompanied by enhanced humoral immune responses. Time-course experiments demonstrated that B cell accumulation preceded overt neuronal loss, while B cell depletion via anti-CD20 antibodies or intravenous immunoglobulin treatment partially rescued the phenotypes. Further protein profiling and cell-based assays suggested that the GABAA receptor may represent one potential neuronal antigen targeted by circulating autoantibodies. Together, these findings identify FAM129C as a genetic contributor to achalasia and support a neuroimmune mechanism in which B cell activation and autoantibody-mediated responses contribute to inhibitory neuronal injury. These results provide important insights into achalasia pathogenesis and highlight the potential of immunomodulatory strategies for disease intervention in the early stage.
2026-05-14 | Esophageal peristalsis in health and disease: mechanistic insights.
The mechanism of esophageal peristalsis or sequential contractions of the skeletal and smooth muscle esophagus resides at multiple levels, i.e., brain stem (central pattern generator), neurons within the wall of the esophagus (myenteric plexus), and smooth muscle (myogenic). Esophageal peristalsis consists of initial inhibition followed by excitation, for which there may be parallel pathways from the central pattern generator, traveling via the vagus nerve to communicate with the inhibitory and excitatory neurons of the myenteric plexus. Primary and secondary esophageal peristalsis are associated with concurrent contraction and relaxation of the circular and longitudinal muscle layers. The longitudinal muscle contraction in the contracted segment exerts mechanical stretch on the segment ahead of it, which likely activates the mechanosensitive inhibitory motor neurons in the myenteric plexus to induce descending relaxation, a peripheral mechanism of the peristaltic reflex. In achalasia esophagus, there is inflammation and fibrosis in the muscularis propria and myenteric plexus, resulting in loss of inhibitory nerves in the myenteric plexus. It also results in replacement of muscle with fibrous tissue in the muscularis propria of the lower esophageal sphincter (LES), impaired LES relaxation, and low distensibility of the esophagogastric junction in achalasia esophagus. The esophageal hiatus contains a pad of fat that is replaced with fibrosis in patients with achalasia esophagus. Whether hiatal fibrosis leads to impaired LES relaxation/low distensibility of the esophagogastric junction and changes in esophageal peristalsis are secondary to obstruction requires further study. Esophageal hypersensitivity is currently the favored mechanism of "angina-like" esophageal pain and refractory heartburn. Spastic or long-duration contractions of the longitudinal muscle of the esophagus may also play a role in the genesis of noncardiac esophageal pain and heartburn sensation.
2026-02-01 | Poster Session II A334 PATTERNS AND DIAGNOSTIC YIELD OF ESOPHAGEAL MOTILITY DISORDERS: A RETROSPECTIVE HIGH-RESOLUTION MOTILITY STUDY
Abstract Background Esophageal motility disorders are underreported in Canada and remain a clinical challenge that impacts quality of life. High-resolution esophageal manometry (HREM) is the gold standard for their diagnosis. Aims Primary Aim: To determine the prevalence of esophageal motility disorders in a population of patients from Southwestern Ontario referred for (HREM). Secondary Aim: To evaluate various HREM parameters across normal and abnormal studies. Methods A retrospective analysis was conducted on patients who underwent HREM at St. Joseph Hospital, in London, Ontario, from Jan 1st, 2014, until Sep 15, 2024. Data was extracted from a motility database of patients who had undergone HREM. The data included patient characteristics, medications, symptoms, and comorbidities, along with indications for HREM, HREM parameters, measurements, and the final diagnosis. Results A total of 1352 patients were included in the final analysis, with the majority being Female (822/1352, 60.8%). Mean age was 54.12 (18-96) years, with an average weight of 80.4 kg (25.4 - 185 kg) and a mean height of 168.03 cm (81–201 cm). The most common indication for HREM was dysphagia (587/1352;43.4%), followed by typical GERD symptoms, both heartburn and regurgitation (514/1352;38%). HREM revealed abnormal findings in 582/1352 (43%) of patients, whereas 770/1352 (57%) had normal study results. Ineffective esophageal motility (IEM) was the most prevalent diagnosis (98/1352; 7.2%), followed by achalasia (95/1352; 7.03%) and EGJ outflow obstruction (31/1352; 2.3%). The prevalence of dysphagia was significantly higher among patients with achalasia (80/95; 84.2%) than among those with normal manometry (282/770; 36.6%; p < 0.001). Referral for GERD symptoms occurred in 53.1% (52/98) of IEM patients versus 42.3% (326/770) of those with normal manometry (p = 0.056), indicating no significant difference. PPI use vs no PPI use was associated with lower LES residual pressure (6.81 ± 8.11 mmHg vs 9.16 ± 10.41 mmHg) and LES basal pressure (24.33 ± 15.85 mmHg vs 28.75 ± 16.98 mmHg), both p < 0.001. Opioid use vs non-opioid use showed higher LES basal pressure (30.57 ± 18.67 vs 25.32 ± 16.11, p = 0.007), but no significant difference in LES residual pressure. Conclusions Most HREM studies were normal, with achalasia and IEM being the most common abnormalities—achalasia mostly in dysphagia referrals and IEM in GERD referrals (not statistically significant). These findings highlight indication-specific likelihoods and HREM’s role in triage. Larger, multicenter studies with adjustments and linked pH/EGD data are needed to confirm their robustness and clinical relevance. Funding Agencies None
2025-12-01 | Gastroesophageal Intussusception After Myotomy for Achalasia.
Gastroesophageal intussusception is a rare but clinically significant condition necessitating prompt diagnosis and management. This highlights the importance of early recognition and intervention to prevent severe complications such as oesophageal perforation. Endoscopic assessment and surgical intervention remain the cornerstone of the management, tailored to the clinical severity and surgeon's expertise. The prognosis largely depends on the timeliness of diagnosis and intervention, with early treatment typically resulting in favourable outcomes.
2025-10-05 | Clinical Evaluation, Etiology and Classification of Esophageal Achalasia
A rare disease, achalasia is the most frequent and best-known esophageal motility disorder. Its etiology is still unclear, but it is thought to result from a progressive loss of myenteric neurons at the cardia level. This leads to the impairment of relaxation of the lower esophageal sphincter (LES), a loss of peristalsis and a progressive dilation of the esophagus. Dysphagia is present in almost all patients; regurgitation, chest pain and weight loss are also frequent. Since dysphagia is an ominous symptom, endoscopy is the first test to be performed in these patients, revealing a somewhat dilated esophagus containing undigested food, as well as a closed cardia requiring gentle endoscope pressure to pass through it. Endoscopy may be negative, however, and further tests may be necessary for the diagnosis. Barium swallow usually reveals the characteristic “bird’s beak” appearance of the cardia, with a dilated esophagus: this allows a classification of achalasia into four stages, stage IV being the most advanced and difficult to treat. High-resolution manometry confirms the absence of LES relaxation and esophageal peristalsis. Moreover, it allows a clinically relevant classification of achalasia into three subtypes, of which subtype 3 is poorly responsive to pneumatic dilation and therefore requires surgery or peroral endoscopic myotomy.
oligonucleotides
2023-06-08 | MicroRNA dysregulation and therapeutic opportunities in esophageal diseases.
MicroRNAs (miRNAs) are a class of small endogenous RNA molecules between 18 and 25 nucleotides long. The primary function of miRNAs is in the posttranscriptional regulation of mRNA targets through RNA interference culminating in mRNA degradation or translational repression. MiRNAs are fundamental in physiological and pathological processes such as cell proliferation, differentiation, apoptosis, and inflammation. Among this includes the uncovered potential of miRNAs in overall esophageal disease with a focus on the clinicopathologic allergic disease eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), and the tumorigenic continuum from Barrett's esophagus (BE) toward esophageal adenocarcinoma (EAC). Although these pathologies are distinct from one another, they share pathophysiological elements such as an intense inflammatory milieu, esophageal dysfunction, and as presented in this review, an overlap in miRNA expression which contributes to overall esophageal disease. The overlap in the dysregulated miRNA transcriptome of these pathologies highlights the key role miRNAs play in contributing to esophageal disease progression. Owing to this notable dysregulation, there is an attractive utility for miRNAs as diagnostic and prognostic biomarkers in esophageal diseases that already require invasive endoscopies and biopsy retrieval. In this review miRNAs within EoE, GERD, BE, EAC, and esophageal achalasia are discussed, as well as reviewing a core set of miRNAs shared in the disease progression among some of these pathologies, along with the potential utility of targeting miRNAs as therapeutic options in overall esophageal disease.
2022-12-30 | Downexpression of miR-200c-3p Contributes to Achalasia Disease by Targeting the PRKG1 Gene
Achalasia is an esophageal smooth muscle motility disorder with unknown pathogenesis. Taking into account our previous results on the downexpression of miR-200c-3p in tissues of patients with achalasia correlated with an increased expression of PRKG1, SULF1, and SYDE1 genes, our aim was to explore the unknown biological interaction between these genes and human miR-200c-3p and if this relation could unravel their functional role in the etiology of achalasia. To search for putative miR-200c-3p binding sites in the 3'-UTR of PRKG1, SULF1 and SYDE1, a bioinformatics tool was used. To test whether PRKG1, SULF1, and SYDE1 are targeted by miR-200c-3p, a dual-luciferase reporter assay and quantitative PCR on HEK293 and fibroblast cell lines were performed. To explore the biological correlation between PRKG1 and miR-200c-3p, an immunoblot analysis was carried out. The overexpression of miR-200c-3p reduced the luciferase activity in cells transfected with a luciferase reporter containing a fragment of the 3'-UTR regions of PRKG1, SULF1, and SYDE1 which included the miR-200c-3p seed sequence. The deletion of the miR-200c-3p seed sequence from the 3'-UTR fragments abrogated this reduction. A negative correlation between miR-200c-3p and PRKG1, SULF1, and SYDE1 expression levels was observed. Finally, a reduction of the endogenous level of PRKG1 in cells overexpressing miR-200c-3p was detected. Our study provides, for the first time, functional evidence about the PRKG1 gene as a direct target and SULF1 and SYDE1 as potential indirect substrates of miR-200c-3p and suggests the involvement of NO/cGMP/PKG signaling in the pathogenesis of achalasia.
small molecules
2026-08-28 | Intraoperative indocyanine green (ICG) fluorescence to assess mucosal integrity during laparoscopic Heller-Dor surgery: a pilot randomized study.
Achalasia is a rare oesophageal motility disorder, and minimally invasive Heller-Dor (HD) surgery remains the gold standard surgical treatment for type I and II disease. Mucosal injury is a relevant intraoperative risk during laparoscopic Heller-Dor (LHD) myotomy. Real-time assessment of mucosal integrity remains challenging. This study aimed to evaluate whether the intraoperative use of Indocyanine Green (ICG) fluorescence during this surgery could reliably assess mucosal integrity and potentially reduce the need for intra- and postoperative additional diagnostic tests. In this prospective pilot randomized study, patients undergoing LHD for type I-II achalasia were randomly assigned (1:1) to intraoperative ICG fluorescence assessment or standard intraoperative evaluation with endoscopy and postoperative contrast radiography. The primary outcome was intraoperative detection of mucosal leaks. Secondary outcomes included operative time, intraoperative and postoperative complications, length of stay, postoperative pain, inflammatory markers, dietary progression and 12-month follow-up (ClinicalTrials.gov Identifier: NCT07181070). Seventy-one patients were included (37 ICG, 34 standard). No significant differences were observed between groups in intraoperative or postoperative complications, postoperative recovery, or inflammatory markers. Operative time was significantly shorter in the ICG group compared with the standard group (median 95 [90-95] vs. 105 [95-110] minutes; p = 0.04). Intraoperative ICG fluorescence is safe and feasible, providing real-time visualization of mucosal integrity during LHD surgery. This technique may represent a valuable adjunct to standard practice, optimizing surgical efficiency and resource utilization. Larger studies are needed to confirm these findings.
2026-06-09 | Prucalopride for recurrent achalasia in a pediatric patient: a Case Report
: Introduction Prucalopride, a prokinetic agent, is beneficial for chronic idiopathic constipation in pediatrics, but its efficacy for upper gastrointestinal motility disorders has not been well explored. Case presentation We present an 11-year old male with type II achalasia who underwent Heller myotomy and Dor fundoplication at age 9 and had recurrence of symptoms one year post-operatively. The patient was evaluated with esophagogastroduodenoscopy (EGD) with biopsy and Functional Luminal Impedance Planimetry Probe (FLIP). Symptoms were determined to be secondary to esophageal dysmotility with ongoing esophagogastrojunction (EGJ) outlet obstruction. The patient had resolution of dysphagia and age-appropriate weight gain after starting prucalopride at 1mg dose, daily, by mouth. His symptoms improved within 30 days after initiation. As of last known follow-up 12 months later, he remained symptom free. We expect to continue the current management indefinitely so long as symptoms remain controlled. Conclusion Prucalopride may be a safe and beneficial escalation of therapy in an attempt to delay or avoid further surgical intervention.
2026-03-25 | Severe pneumonia and bloodstream dissemination caused by Mycobacterium houstonense in a patient with achalasia: clinical importance of genospecies typing.
BACKGROUND: Infections caused by members of the Mycobacterium fortuitum complex are generally mild and confined to skin and soft tissues, while severe disease in immunocompetent individuals is uncommon. Within the Mycobacterium fortuitum complex, the unnamed third biovariant complex comprises several closely related species that cannot be reliably distinguished using routine molecular diagnostic methods. Importantly, species within this complex show marked interspecies variability in antimicrobial susceptibility, including predictable intrinsic resistance patterns, with direct consequences for empiric treatment selection in severe infections. Because antimicrobial susceptibility testing for rapidly growing mycobacteria typically requires at least one week, rapid and accurate species-level identification is essential to guide effective early therapy. CASE PRESENTATION: We report a case of life-threatening pneumonia with bloodstream dissemination caused by a third-biovariant M. fortuitum complex species in an otherwise immunocompetent 44-year-old woman with previously undiagnosed achalasia. Routine diagnostics identified the isolate as belonging to the M. fortuitum complex but were insufficient for species-level identification. Whole-genome sequencing was performed and identified the pathogen as Mycobacterium houstonense, a species historically considered rare in human disease. The patient developed severe respiratory failure and sepsis, requiring prolonged intensive care treatment. Targeted antimicrobial therapy guided by species identification, combined with treatment of the underlying achalasia, led to gradual clinical improvement, although prolonged antimicrobial therapy was required to achieve culture conversion. CONCLUSIONS: This case represents, to our knowledge, the first reported case in which M. houstonense was isolated from blood cultures in association with invasive disease. It demonstrates that infections caused by species within the unnamed third biovariant M. fortuitum complex can be severe and that reliance on complex-level identification alone may delay appropriate empiric therapy. Rapid genospecies identification is therefore crucial in severe infections caused by species within the unnamed third biovariant M. fortuitum complex, particularly when antimicrobial susceptibility is known to vary markedly between closely related species.
2026-01-01 | Experience in administration of an esophageal protective agent in patients with achalasia cardia and Barrett's esophagus
Achalasia cardia (AC) and Barrett's esophagus (BE) are precancerous conditions whose relevance is associated with a significant increase in the morbidity over the past 30 years and a high risk of esophageal adenocarcinoma. Despite different mechanisms of development, these diseases have similar clinical presentations (regurgitation, swallowing disorders, cough, chest pain, heartburn) and share some tissue changes related to inflammation in the esophageal mucosa. Gastroesophageal reflux disease (GERD) plays a key role in both conditions: as a cause of BE and as an adverse clinical outcome in patients wi th AC. Both diseases share a common mechanism of tissue changes suc h as damaged mucosal barrier, impaired apical junction complex, dilated intercellular spaces, and the disease progression. In patients with AC, pneumatic dilation of the cardia and incision of the esophagogastric junction muscles lead to damage of muscle fibers and inflammation. As for BE, radiofrequency ablation of the metaplastic esophageal tissue also affects the mucosa. Clinical case reports of patients with BE and AC demonstrate efficacy of an esophageal protective agent including sodium hyaluronate, sodium chondroitin sulfate, and Poloxamer 407. Owing to reliable protection of the esophageal mucosa, inflammation reduction, and recovery of intercellular connections, it may be used to treat BE and AC along with background therapy. KEYWORDS: Barrett's esophagus, achalasia cardia, GERD, esophageal protective agent, case reports. FOR CITATION: Ufimtseva I.V., Yakovleva S.V., Blagikh A.V. Experience in administration of an esophageal protective agent in patients with achalasia cardia and Barrett's esophagus. Russian Medical Inquiry. 2026;10(5):326–333 (in Russ.). DOI: 10.32364/2587-6821- 2026-10-5-9
2025-11-17 | Postoperative Nausea and Vomiting Between Total Intravenous and Sevoflurane Anesthesia after Peroral Endoscopic Myotomy; A Randomized, Double-Blind
Peroral endoscopic myotomy (POEM) recently has been reported as minimally invasive therapy for esophageal achalasia requires general anesthesia. Postoperative nausea and vomiting (PONV) is one of the most common adverse events after general anesthesia. Although PONV is associated with adverse consequences undergoing POEM, little has been known about the incidence and risk factors. We evaluated the incidence of PONV undergoing POEM as well as the relationship between incidences and anesthetic agents. This prospective double-blind study comprised 60 patients with American Society of Anesthesiologist physical status I or II who were undergoing POEM with inhaled anesthesia or TIVA. Patients were interviewed by two experienced anesthesiologists about incidence of PONV in accordance with a categorical verbal rating scale (VAS) and PONV Intensity Scale. The primary outcome was the incidence of PONV undergoing POEM between the two groups. In addition, we observed postoperative outcomes including bleeding at surgical site, mucosal injury, and patients’ satisfaction. The incidence of PONV after POEM within first 6 hours was significant lower in the TIVA group than in the sevoflurane group (46.4% vs 76.7%, p=0.025). Additionally, it was observed that number of patients who experienced postoperative complications, such as surgical site injury, mucosal injury, heart burn, pneumoperitoneum, and emphysema, was higher in TIVA group (44.4%) compared with in sevoflurane group (26.7%), but it was insignificant (p=0.130). These data suggest that TIVA could be considered as a good method to prevent PONV during early postoperative period (within 6 hours) after POEM.
proteins
2025-11-14 | Clinical Utility of Botulinum Toxin Injections in Children with Gastrointestinal Disorders.
To review the clinical utility of botulinum toxin (BTX) injections in children with gastrointestinal (GI) disorders. BTX is a presynaptic acetylcholine inhibitor with medical indications ranging from the treatment of muscle spasticity to gastrointestinal disorders involving sphincter dysfunction. BTX injections to the upper esophageal sphincter are used to target cricopharyngeal achalasia and retrograde cricopharyngeal dysfunction as temporary measures to decrease sphincter tone and improve swallowing, potentially eliminating the need for surgery. Lower esophageal and pyloric BTX injections have shown benefit in achalasia and gastroparesis, particularly in children unable to undergo or refractory to definitive treatments. Anorectal indications represent the largest experience, especially in children with persistent obstructive defecation symptoms after surgery for Hirschsprung's disease. BTX injection is a minimally invasive, reversible, and generally well-tolerated intervention with mild, self-limited side effects. However, its limitations include transient effects, procedural variability, and primarily off-label use, with most pediatric experience derived from small series. Prospective studies are needed to further evaluate patient selection, standardization, dosage, and long-term efficacy in pediatric gastrointestinal disorders.
2025-09-29 | Diagnostic and Therapeutic Challenges in a Case of Achalasia Masquerading as Gastroesophageal Reflux Disease (GERD).
Achalasia is a rare swallowing disorder that occurs due to the deterioration of the inhibitory neurons that control the lower esophageal sphincter (LES). Achalasia shares many clinical characteristics and symptoms with gastroesophageal reflux disease (GERD), a common process involving reflux of stomach acid into the esophagus, causing difficulties in differentiating diagnoses for therapeutic management. We report the case of a 49-year-old male patient with a history of chronic GERD who presented with dysphagia. Despite proton pump inhibitor (PPI) therapy, the patient developed worsening dysphagia. Esophagogastroduodenoscopy (EGD) suggested a diagnosis of achalasia, later confirmed with barium esophagram and manometry. Due to worsening symptoms and concerns about surgical fitness, the patient underwent bridge Botox therapy. However, further deterioration necessitated surgical myotomy. This case highlights the importance of a full dysphagia evaluation, including barium esophagram and EGD. This case also highlights the treatment of achalasia, which may include Botox injections as bridge therapy and myotomy for complete resolution.
2025-09-22 | When Two Roads Intersect: Coexisting Achalasia Cardia and Oesophageal Varices as a Therapeutic Dilemma.
Achalasia is a rare cause of oesophageal dysmotility. This disorder causes impaired relaxation of the lower oesophageal sphincter (LOS), impacting peristalsis and the normal movement of food through the digestive tract, resulting in worsening swallowing difficulty, known as dysphagia. Although various effective treatments are available, like pneumatic dilation, laparoscopic Heller myotomy, and peroral endoscopic myotomy (POEM), patients with portal hypertension may develop oesophageal varices, which complicates treatment due to the heightened risk of severe bleeding. We present the case of a 45-year-old man with a history of cirrhosis and chronic hepatitis C who developed progressively worsening dysphagia over four months, which led to significant weight loss over this period and prompted further investigation. An oesophagogastroduodenoscopy (OGD) showed a dilated oesophagus with retained food contents and grade II oesophageal varices without any endoscopic red signs. Additionally, a barium swallow and high-resolution manometry were done, which led to the confirmation of the diagnosis of achalasia cardia. Given the high risk of bleeding associated with conventional therapies in the presence of varices, a safer, minimally invasive approach was chosen. Botulinum toxin was carefully injected into the LOS under endoscopic ultrasound (EUS) guidance to avoid the variceal sites and negate the risk of bleeding. This approach allowed targeted treatment of achalasia while minimising the risk of variceal bleeding. The patient experienced significant improvement in dysphagia without complications. This case highlights the rare and challenging coexistence of achalasia and oesophageal varices. It highlights the need for considering individualised treatment strategies in high-risk individuals.
2025-08-27 | Efficacy of esophageal balloon dilatation with Botox injection in children with achalasia referred to a tertiary care center.
Achalasia is an esophageal motility disorder with symptoms like regurgitation, dysphagia, anorexia, and chronic cough. Effective treatments include pneumatic dilatation and myotomy. This study evaluated the combined use of botulinum toxin (Botox) injection and esophageal balloon dilation versus balloon dilation alone, analyzing recovery rates for gastrointestinal and non-gastrointestinal symptoms. This clinical trial involved an intervention group and historical controls. Patients with symptomatic achalasia referred to Mofid Hospital (2020-2023) received balloon dilatation with Botox injection. Historical controls had balloon dilatation alone. Botox was injected in the Lower Esophageal Sphincter (LES) at four points before balloon dilatation. Symptoms and growth parameters were monitored every three months for a year, then every six months, with annual follow-ups for three years. The study included 37 intervention and 31 control patients, and data were analyzed using SPSS 24 software. From the onset of the study to the 36th month, the intervention group showed greater symptom improvement than the control group: nausea or vomiting (21.8%), regurgitation (37.2%), dysphagia to liquids (25%), dysphagia to solids (25.6%), Globus sensation (13.5%), anorexia (19.6%), weight loss (21.3%), halitosis (22.3%), cough (16.8%), aspiration (20%), and refusal to eat (7%). Exceptions were chest pain (almost the same in both groups) and heartburn (1.1% better in the control group). At 6 and 12 months, the intervention group improved in abdominal tenderness (9.8%), wheezing (11.9%), and coarse rales (16.8%). Radiological signs improved more in the intervention group: esophageal dilatation (9.8%), rat tail/bird beak sign (33.7%), tertiary contractions (6.5%), and reduced air-fluid level 3 and 2 in the esophagus respectively (upper to middle third: 12.5%, middle to lower third: 8.4%) and the exception was sigmoid esophagus which was almost the same in both groups (3.9%). At 36 months, growth criteria in the intervention group increased: length (5.8 cm), BMI (1.87 units), Z score (0.91 units), and percentile (14.7 units). The combined balloon and Botox treatment has shown effectiveness in improving disease symptoms, physical examination results, growth criteria, and radiological findings. Further studies are recommended to establish this approach as a potential national protocol.
2024-10-07 | Botulinum toxin injection of the lower esophageal sphincter to identify achalasia-variant esophagogastric junction outflow obstruction.
Esophagogastric junction outflow obstruction (EGJOO) can be an achalasia variant caused by neuromuscular dysfunction of the lower esophageal sphincter (LES), or the manometric manifestation of mechanical processes that impair EGJ distensibility. Distinction among these conditions has important implications for treatment, but can be difficult. We hypothesized that response to botulinum toxin (BT) injection of the LES could be a diagnostic test for identifying achalasia-variant EGJOO likely to respond to LES muscle-directed invasive therapy. We reviewed our experience with symptomatic EGJOO patients who had BT injection of the LES. Data collected include demographics, esophageal body manometry findings, esophagram evidence of retention, and symptom response at 1-6 months after BT injection categorized as poor, partial, or good. Clinical response to any subsequent LES-directed invasive treatment (EsoFLIP dilation, pneumatic dilation, Heller myotomy, or POEM) also was recorded. Thirteen symptomatic EGJOO patients were included (mean age 55.9 ± 16.4 years; eight men, five women). Symptom response to BT injection was good in six (46%), partial in three (23%), and poor in three (23%); one was lost to follow-up. All five patients who received invasive treatment after partial or good response to BT had a partial or good response to invasive treatment. The one patient who had invasive treatment after a poor response to BT had a poor response to invasive treatment. These findings suggest that a good response to BT injection of the LES can identify an achalasia-variant form of EGJOO that will respond to LES muscle-directed invasive therapy.
antibodies
2026-05-26 | A frameshift variant in FAM129C contributes to achalasia through B cell responses against the GABAA receptor.
Achalasia is a rare esophageal motility disorder of poorly understood etiology. Here, we perform a large trio-based whole-genome sequencing study of achalasia and identify a recessively inherited frameshift variant in FAM129C (p.Ala454fs). A CRISPR/Cas9-engineered Fam129c-mutant mouse model recapitulating key features of achalasia was established, including growth retardation, elevated lower esophageal sphincter (LES) pressure, and selective loss of inhibitory neurons. Multi-omic analyses revealed substantial B cell expansion and activation within the LES, accompanied by enhanced humoral immune responses. Time-course experiments demonstrated that B cell accumulation preceded overt neuronal loss, while B cell depletion via anti-CD20 antibodies or intravenous immunoglobulin treatment partially rescued the phenotypes. Further protein profiling and cell-based assays suggested that the GABAA receptor may represent one potential neuronal antigen targeted by circulating autoantibodies. Together, these findings identify FAM129C as a genetic contributor to achalasia and support a neuroimmune mechanism in which B cell activation and autoantibody-mediated responses contribute to inhibitory neuronal injury. These results provide important insights into achalasia pathogenesis and highlight the potential of immunomodulatory strategies for disease intervention in the early stage.
2026-05-14 | Esophageal peristalsis in health and disease: mechanistic insights.
The mechanism of esophageal peristalsis or sequential contractions of the skeletal and smooth muscle esophagus resides at multiple levels, i.e., brain stem (central pattern generator), neurons within the wall of the esophagus (myenteric plexus), and smooth muscle (myogenic). Esophageal peristalsis consists of initial inhibition followed by excitation, for which there may be parallel pathways from the central pattern generator, traveling via the vagus nerve to communicate with the inhibitory and excitatory neurons of the myenteric plexus. Primary and secondary esophageal peristalsis are associated with concurrent contraction and relaxation of the circular and longitudinal muscle layers. The longitudinal muscle contraction in the contracted segment exerts mechanical stretch on the segment ahead of it, which likely activates the mechanosensitive inhibitory motor neurons in the myenteric plexus to induce descending relaxation, a peripheral mechanism of the peristaltic reflex. In achalasia esophagus, there is inflammation and fibrosis in the muscularis propria and myenteric plexus, resulting in loss of inhibitory nerves in the myenteric plexus. It also results in replacement of muscle with fibrous tissue in the muscularis propria of the lower esophageal sphincter (LES), impaired LES relaxation, and low distensibility of the esophagogastric junction in achalasia esophagus. The esophageal hiatus contains a pad of fat that is replaced with fibrosis in patients with achalasia esophagus. Whether hiatal fibrosis leads to impaired LES relaxation/low distensibility of the esophagogastric junction and changes in esophageal peristalsis are secondary to obstruction requires further study. Esophageal hypersensitivity is currently the favored mechanism of "angina-like" esophageal pain and refractory heartburn. Spastic or long-duration contractions of the longitudinal muscle of the esophagus may also play a role in the genesis of noncardiac esophageal pain and heartburn sensation.
2026-02-01 | Poster Session II A334 PATTERNS AND DIAGNOSTIC YIELD OF ESOPHAGEAL MOTILITY DISORDERS: A RETROSPECTIVE HIGH-RESOLUTION MOTILITY STUDY
Abstract Background Esophageal motility disorders are underreported in Canada and remain a clinical challenge that impacts quality of life. High-resolution esophageal manometry (HREM) is the gold standard for their diagnosis. Aims Primary Aim: To determine the prevalence of esophageal motility disorders in a population of patients from Southwestern Ontario referred for (HREM). Secondary Aim: To evaluate various HREM parameters across normal and abnormal studies. Methods A retrospective analysis was conducted on patients who underwent HREM at St. Joseph Hospital, in London, Ontario, from Jan 1st, 2014, until Sep 15, 2024. Data was extracted from a motility database of patients who had undergone HREM. The data included patient characteristics, medications, symptoms, and comorbidities, along with indications for HREM, HREM parameters, measurements, and the final diagnosis. Results A total of 1352 patients were included in the final analysis, with the majority being Female (822/1352, 60.8%). Mean age was 54.12 (18-96) years, with an average weight of 80.4 kg (25.4 - 185 kg) and a mean height of 168.03 cm (81–201 cm). The most common indication for HREM was dysphagia (587/1352;43.4%), followed by typical GERD symptoms, both heartburn and regurgitation (514/1352;38%). HREM revealed abnormal findings in 582/1352 (43%) of patients, whereas 770/1352 (57%) had normal study results. Ineffective esophageal motility (IEM) was the most prevalent diagnosis (98/1352; 7.2%), followed by achalasia (95/1352; 7.03%) and EGJ outflow obstruction (31/1352; 2.3%). The prevalence of dysphagia was significantly higher among patients with achalasia (80/95; 84.2%) than among those with normal manometry (282/770; 36.6%; p < 0.001). Referral for GERD symptoms occurred in 53.1% (52/98) of IEM patients versus 42.3% (326/770) of those with normal manometry (p = 0.056), indicating no significant difference. PPI use vs no PPI use was associated with lower LES residual pressure (6.81 ± 8.11 mmHg vs 9.16 ± 10.41 mmHg) and LES basal pressure (24.33 ± 15.85 mmHg vs 28.75 ± 16.98 mmHg), both p < 0.001. Opioid use vs non-opioid use showed higher LES basal pressure (30.57 ± 18.67 vs 25.32 ± 16.11, p = 0.007), but no significant difference in LES residual pressure. Conclusions Most HREM studies were normal, with achalasia and IEM being the most common abnormalities—achalasia mostly in dysphagia referrals and IEM in GERD referrals (not statistically significant). These findings highlight indication-specific likelihoods and HREM’s role in triage. Larger, multicenter studies with adjustments and linked pH/EGD data are needed to confirm their robustness and clinical relevance. Funding Agencies None
2025-12-01 | Gastroesophageal Intussusception After Myotomy for Achalasia.
Gastroesophageal intussusception is a rare but clinically significant condition necessitating prompt diagnosis and management. This highlights the importance of early recognition and intervention to prevent severe complications such as oesophageal perforation. Endoscopic assessment and surgical intervention remain the cornerstone of the management, tailored to the clinical severity and surgeon's expertise. The prognosis largely depends on the timeliness of diagnosis and intervention, with early treatment typically resulting in favourable outcomes.
2025-10-05 | Clinical Evaluation, Etiology and Classification of Esophageal Achalasia
A rare disease, achalasia is the most frequent and best-known esophageal motility disorder. Its etiology is still unclear, but it is thought to result from a progressive loss of myenteric neurons at the cardia level. This leads to the impairment of relaxation of the lower esophageal sphincter (LES), a loss of peristalsis and a progressive dilation of the esophagus. Dysphagia is present in almost all patients; regurgitation, chest pain and weight loss are also frequent. Since dysphagia is an ominous symptom, endoscopy is the first test to be performed in these patients, revealing a somewhat dilated esophagus containing undigested food, as well as a closed cardia requiring gentle endoscope pressure to pass through it. Endoscopy may be negative, however, and further tests may be necessary for the diagnosis. Barium swallow usually reveals the characteristic “bird’s beak” appearance of the cardia, with a dilated esophagus: this allows a classification of achalasia into four stages, stage IV being the most advanced and difficult to treat. High-resolution manometry confirms the absence of LES relaxation and esophageal peristalsis. Moreover, it allows a clinically relevant classification of achalasia into three subtypes, of which subtype 3 is poorly responsive to pneumatic dilation and therefore requires surgery or peroral endoscopic myotomy.
oligonucleotides
2023-06-08 | MicroRNA dysregulation and therapeutic opportunities in esophageal diseases.
MicroRNAs (miRNAs) are a class of small endogenous RNA molecules between 18 and 25 nucleotides long. The primary function of miRNAs is in the posttranscriptional regulation of mRNA targets through RNA interference culminating in mRNA degradation or translational repression. MiRNAs are fundamental in physiological and pathological processes such as cell proliferation, differentiation, apoptosis, and inflammation. Among this includes the uncovered potential of miRNAs in overall esophageal disease with a focus on the clinicopathologic allergic disease eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), and the tumorigenic continuum from Barrett's esophagus (BE) toward esophageal adenocarcinoma (EAC). Although these pathologies are distinct from one another, they share pathophysiological elements such as an intense inflammatory milieu, esophageal dysfunction, and as presented in this review, an overlap in miRNA expression which contributes to overall esophageal disease. The overlap in the dysregulated miRNA transcriptome of these pathologies highlights the key role miRNAs play in contributing to esophageal disease progression. Owing to this notable dysregulation, there is an attractive utility for miRNAs as diagnostic and prognostic biomarkers in esophageal diseases that already require invasive endoscopies and biopsy retrieval. In this review miRNAs within EoE, GERD, BE, EAC, and esophageal achalasia are discussed, as well as reviewing a core set of miRNAs shared in the disease progression among some of these pathologies, along with the potential utility of targeting miRNAs as therapeutic options in overall esophageal disease.
2022-12-30 | Downexpression of miR-200c-3p Contributes to Achalasia Disease by Targeting the PRKG1 Gene
Achalasia is an esophageal smooth muscle motility disorder with unknown pathogenesis. Taking into account our previous results on the downexpression of miR-200c-3p in tissues of patients with achalasia correlated with an increased expression of PRKG1, SULF1, and SYDE1 genes, our aim was to explore the unknown biological interaction between these genes and human miR-200c-3p and if this relation could unravel their functional role in the etiology of achalasia. To search for putative miR-200c-3p binding sites in the 3'-UTR of PRKG1, SULF1 and SYDE1, a bioinformatics tool was used. To test whether PRKG1, SULF1, and SYDE1 are targeted by miR-200c-3p, a dual-luciferase reporter assay and quantitative PCR on HEK293 and fibroblast cell lines were performed. To explore the biological correlation between PRKG1 and miR-200c-3p, an immunoblot analysis was carried out. The overexpression of miR-200c-3p reduced the luciferase activity in cells transfected with a luciferase reporter containing a fragment of the 3'-UTR regions of PRKG1, SULF1, and SYDE1 which included the miR-200c-3p seed sequence. The deletion of the miR-200c-3p seed sequence from the 3'-UTR fragments abrogated this reduction. A negative correlation between miR-200c-3p and PRKG1, SULF1, and SYDE1 expression levels was observed. Finally, a reduction of the endogenous level of PRKG1 in cells overexpressing miR-200c-3p was detected. Our study provides, for the first time, functional evidence about the PRKG1 gene as a direct target and SULF1 and SYDE1 as potential indirect substrates of miR-200c-3p and suggests the involvement of NO/cGMP/PKG signaling in the pathogenesis of achalasia.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.